FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894921161> ?p ?o ?g. }

• W2894921161 endingPage "526" @default.
• W2894921161 startingPage "517" @default.
• W2894921161 abstract "Noninvasively differentiating therapy-induced pseudoprogression from recurrent disease in patients with glioblastoma is prospectively difficult due to the current lack of a biologically specific imaging metric. Ferumoxytol iron oxide nanoparticle MRI contrast characterizes innate immunity mediated neuroinflammation; therefore, we hypothesized that combined ferumoxytol and gadolinium enhanced MRI could serve as a biomarker of glioblastoma pseudoprogression. In this institutional review board-approved, retrospective study, we analyzed ferumoxytol and gadolinium contrast enhanced T1-weighted 3T MRI in 45 patients with glioblastoma over multiple clinical timepoints. Isocitrate dehydrogenase 1 (IDH-1) mutational status was characterized by exome sequencing. Sum of products diameter measurements were calculated according to Response Assessment in Neuro-Oncology criteria from both gadolinium and ferumoxytol enhanced sequences. Enhancement mismatch was calculated as the natural log of the ferumoxytol to gadolinium sum of products diameter ratio. Analysis of variance and Student’s t-test assessed differences in mismatch ratios. P-value <0.05 indicated statistical significance. With the development of pseudoprogression we observed a significantly elevated mismatch ratio compared with disease recurrence (P < 0.01) within IDH-1 wild type patients. Patients with IDH-1 mutation demonstrated significantly reduced mismatch ratio with the development of pseudoprogression compared with disease recurrence (P < 0.01). Receiver operator curve analysis demonstrated 100% sensitivity and specificity for the use of mismatch ratios as a diagnostic biomarker of pseudoprogression. Our study suggests that ferumoxytol to gadolinium contrast mismatch ratios are an MRI biomarker for the diagnosis of pseudoprogression in patients with glioblastoma. This may be due to the unique characterization of therapy-induced neuroinflammation." @default.
• W2894921161 created "2018-10-12" @default.
• W2894921161 creator A5000311910 @default.
• W2894921161 creator A5003143439 @default.
• W2894921161 creator A5003425834 @default.
• W2894921161 creator A5011949350 @default.
• W2894921161 creator A5012578184 @default.
• W2894921161 creator A5014421826 @default.
• W2894921161 creator A5014536479 @default.
• W2894921161 creator A5027833002 @default.
• W2894921161 creator A5028716409 @default.
• W2894921161 creator A5036618990 @default.
• W2894921161 creator A5039007240 @default.
• W2894921161 creator A5040686327 @default.
• W2894921161 creator A5046389664 @default.
• W2894921161 creator A5048805399 @default.
• W2894921161 creator A5048927825 @default.
• W2894921161 creator A5051808588 @default.
• W2894921161 creator A5058599914 @default.
• W2894921161 creator A5070140716 @default.
• W2894921161 creator A5083401716 @default.
• W2894921161 creator A5086248029 @default.
• W2894921161 creator A5086633896 @default.
• W2894921161 date "2018-10-01" @default.
• W2894921161 modified "2023-10-17" @default.
• W2894921161 title "Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression" @default.
• W2894921161 cites W1957500099 @default.
• W2894921161 cites W1973206036 @default.
• W2894921161 cites W1992646913 @default.
• W2894921161 cites W1993605227 @default.
• W2894921161 cites W2011276562 @default.
• W2894921161 cites W2016045856 @default.
• W2894921161 cites W2019427875 @default.
• W2894921161 cites W2027851837 @default.
• W2894921161 cites W2032940213 @default.
• W2894921161 cites W2036044314 @default.
• W2894921161 cites W2036541538 @default.
• W2894921161 cites W2039289142 @default.
• W2894921161 cites W2055718468 @default.
• W2894921161 cites W2060895562 @default.
• W2894921161 cites W2073299459 @default.
• W2894921161 cites W2080274549 @default.
• W2894921161 cites W2083261882 @default.
• W2894921161 cites W2084495605 @default.
• W2894921161 cites W2087201765 @default.
• W2894921161 cites W2092736872 @default.
• W2894921161 cites W2092877053 @default.
• W2894921161 cites W2093711649 @default.
• W2894921161 cites W2096287682 @default.
• W2894921161 cites W2098568687 @default.
• W2894921161 cites W2105100844 @default.
• W2894921161 cites W2107731988 @default.
• W2894921161 cites W2108201515 @default.
• W2894921161 cites W2112014411 @default.
• W2894921161 cites W2118311655 @default.
• W2894921161 cites W2127901599 @default.
• W2894921161 cites W2131724940 @default.
• W2894921161 cites W2133611748 @default.
• W2894921161 cites W2141644151 @default.
• W2894921161 cites W2142188858 @default.
• W2894921161 cites W2148216778 @default.
• W2894921161 cites W2158681922 @default.
• W2894921161 cites W2160445648 @default.
• W2894921161 cites W2162643152 @default.
• W2894921161 cites W2163203871 @default.
• W2894921161 cites W2165871546 @default.
• W2894921161 cites W2323543821 @default.
• W2894921161 cites W2337855347 @default.
• W2894921161 cites W2365629726 @default.
• W2894921161 cites W2515595382 @default.
• W2894921161 cites W2535346732 @default.
• W2894921161 cites W2604221352 @default.
• W2894921161 cites W2607015440 @default.
• W2894921161 cites W2626784949 @default.
• W2894921161 doi "https://doi.org/10.1093/neuonc/noy160" @default.
• W2894921161 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6422439" @default.
• W2894921161 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30277536" @default.
• W2894921161 hasPublicationYear "2018" @default.
• W2894921161 type Work @default.
• W2894921161 sameAs 2894921161 @default.
• W2894921161 citedByCount "27" @default.
• W2894921161 countsByYear W28949211612019 @default.
• W2894921161 countsByYear W28949211612020 @default.
• W2894921161 countsByYear W28949211612021 @default.
• W2894921161 countsByYear W28949211612022 @default.
• W2894921161 countsByYear W28949211612023 @default.
• W2894921161 crossrefType "journal-article" @default.
• W2894921161 hasAuthorship W2894921161A5000311910 @default.
• W2894921161 hasAuthorship W2894921161A5003143439 @default.
• W2894921161 hasAuthorship W2894921161A5003425834 @default.
• W2894921161 hasAuthorship W2894921161A5011949350 @default.
• W2894921161 hasAuthorship W2894921161A5012578184 @default.
• W2894921161 hasAuthorship W2894921161A5014421826 @default.
• W2894921161 hasAuthorship W2894921161A5014536479 @default.
• W2894921161 hasAuthorship W2894921161A5027833002 @default.
• W2894921161 hasAuthorship W2894921161A5028716409 @default.
• W2894921161 hasAuthorship W2894921161A5036618990 @default.
• W2894921161 hasAuthorship W2894921161A5039007240 @default.

• next